Brereton H D, Bryant T L, Young R C
Cancer Res. 1975 Sep;35(9):2420-5.
Single doses of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea caused transient suppression of [3H]thymidine incorporation into DNA in bone marrow and gastrointestinal mucosa and more prolonged inhibition of such incorporation in B16 melanoma. A single dose of 1-(2-chloroethyl) -3- (trans-4-methylcyclohexyl) -1-nitro-sourea, 16 mg/kg, doubled the mean life-span after treatment of C57BL times DBA/2F1 male mice bearing 12-day-old B16 melanomas. Subsequent doses timed to minimize toxicity and maximize antitumor effect, however, produced no further prolongation of survival, and studies with B16 melanoma previously expsed to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea demonstrated that the suppression of [3H]thymidine incorporation into DNA was no longer prolonged beyond that seen with normal host tissues. The loss of clinical efficacy was accompanied by a loss of differential suppression of [3H]thymidine incorporation into DNA between the tumor and host tissues.
单剂量的1-(2-氯乙基)-3-(反式-4-甲基环己基)-1-亚硝基脲可导致骨髓和胃肠道黏膜中[3H]胸腺嘧啶核苷掺入DNA的短暂抑制,而在B16黑色素瘤中这种掺入的抑制作用持续时间更长。单剂量16mg/kg的1-(2-氯乙基)-3-(反式-4-甲基环己基)-1-亚硝基脲可使携带12日龄B16黑色素瘤的C57BL×DBA/2F1雄性小鼠治疗后的平均寿命延长一倍。然而,后续为使毒性最小化和抗肿瘤效果最大化而安排的剂量并未进一步延长生存期,并且对先前暴露于1-(2-氯乙基)-3-(反式-4-甲基环己基)-1-亚硝基脲的B16黑色素瘤的研究表明,[3H]胸腺嘧啶核苷掺入DNA的抑制作用不再比正常宿主组织中观察到的持续时间更长。临床疗效的丧失伴随着肿瘤组织与宿主组织之间[3H]胸腺嘧啶核苷掺入DNA的差异抑制作用的丧失。